| Entries |
| Document | Title | Date |
|---|
| 20080207732 | Pyrrolidine Derivatives as Histamine H3 Receptor Antagonists - The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. | 08-28-2008 |
| 20080214648 | Hiv Prodrugs Cleavable by Cd26 - The present invention provides new prodrugs which are conjugates of a therapeutic compound and a peptide wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present prodrugs have the formula | 09-04-2008 |
| 20080255220 | Therapeutic Substituted Gamma Lactams - Disclosed herein is a compound comprising | 10-16-2008 |
| 20080255221 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS - The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed. | 10-16-2008 |
| 20080262073 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity - The invention describes new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. | 10-23-2008 |
| 20080269313 | Prolyl Oligopeptidase Inhibitors Ameliorating Recovery From Brain Trauma - The present invention relates to a method for the treatment of sensorimotor dysfunctions caused by brain trauma with an inhibitor of prolyl oligopeptidase or a pharmaceutically acceptable ester or salt thereof. | 10-30-2008 |
| 20080300292 | Nitrosated and Nitrosylated Compounds, Compositions and Methods for the Treatment of Ophthalmic Disorders - The invention describes novel nitrosated and/or nitrosylated compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one compound of the invention, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor compound and/or at least one therapeutic agent. The invention also provides methods for treating ophthalmic disorders. The nitrosated and/or nitrosylated compounds are preferably nitrosated and/or nitrosylated (3-adrenergic antagonists and nitrosated and/or nitrosylated angiotensin-converting enzyme (ACE) inhibitors. | 12-04-2008 |
| 20090005431 | SUBSTITUTED PYRROLIDINES - Disclosed herein are substituted pyrrolidine-based muscarinic receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 01-01-2009 |
| 20090012148 | REDUCING CELLULAR CHOLESTEROL LEVELS AND/OR TREATING OR PREVENTING PHOSPHOLIPIDOSIS - Compounds disclosed herein may be used in disclosed methods for reducing the amount of cholesterol in a cell, for treating a patient suffering from a disorder characterized by cellular accumulation of cholesterol (such as Niemann-Pick Disease Type C or atherosclerosis), and/or for treating or preventing phospholipidosis. In some embodiments, the compounds may include a pyrrolone or triazine moiety. | 01-08-2009 |
| 20090012149 | PRODRUG OF AN ICE INHIBITOR - This invention describes an ICE inhibitor prodrug (I) having good bioavailability. | 01-08-2009 |
| 20090048328 | Compound Comprising Prodigiosin From Serratia Macescence B-1231 Kctc 0386Bp for Prevention and Treatment of Acute Graft-Versus-Host Disease - This invention relates to a composition for the prevention and treatment of acute graft-versus-host disease comprising prodigiosin isolated from | 02-19-2009 |
| 20090069402 | DEUTERIUM-ENRICHED ATRASENTAN - The present application describes deuterium-enriched atrasentan, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-12-2009 |
| 20090099249 | THERAPEUTIC LACTAMS - Disclosed herein is a compound having a structure | 04-16-2009 |
| 20090149528 | Cinnamic acid amides - The present invention relates to compounds, to processes for preparing them, to pharmaceutical compositions comprising them, and to their use in the therapy and/or prophylaxis in illnesses in people or animals, especially diseases of bacterial infection. | 06-11-2009 |
| 20090203762 | METHODS FOR THE PRODUCTION OF BILIVERDIN - The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially | 08-13-2009 |
| 20090221666 | STILBENE DERIVATIVES AND METHODS OF INHIBITING CANCER CELL GROWTH AND MICROBIAL GROWTH - The present invention provides stilbene derived compounds having antineoplastic and/or antimicrobial activity. Preferred compounds of the invention include compounds of the formula (I) wherein R is Dap, Dap-Dil, Dap-Dil-Val, or Dap-Dil-Val-Dov; R | 09-03-2009 |
| 20090281161 | Organic Compounds - Novel 3,4-di-, 3,3,4-di-, 3,4,4,-tri- and 3,3,4,4-tetra-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula (I) wherein the substituents are as described in the specification. | 11-12-2009 |
| 20090306172 | Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent - An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea. | 12-10-2009 |
| 20100004310 | PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF ALZHEIMER'S DISEASE - The present invention relate to pharmaceutical formulations that include a CPHPC component and a delivery agent compound. | 01-07-2010 |
| 20100041730 | ALKYLATED HETEROCYCLIC REACTION PRODUCTS USEFUL AS ANTIOXIDANTS - This invention relates to novel macromolecular compositions having oxidation inhibition characteristics that are exhibited when added to organic material normally susceptible to oxidative degradation in the presence of air or oxygen, such a petroleum products, synthetic polymers, and elastomeric substances. | 02-18-2010 |
| 20100048664 | THERAPEUTIC SUBSTITUTED PYRROLES - Disclosed herein is a compound represented by a formula: | 02-25-2010 |
| 20100063129 | METABOLITES OF WORTMANNIN ANALOGS AND METHODS OF USING THE SAME - Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein. | 03-11-2010 |
| 20100081701 | FAP inhibitors - The present invention concerns compounds, according to general formula (I), which find utility preferably for the treatment of cancer. | 04-01-2010 |
| 20100093824 | METHODS OF TREATING VIRAL INFECTION - The present invention provides methods of treating an RNA viral infection, generally involving administering an agent that reduces the activity of a host cell protein required for maturation of a viral protein, where the emergence of variant virus resistant to the agent is reduced. The present invention further provides combination therapies for viral infection, involving administration of two or more agents that reduce the activity of a host cell protein required for maturation of a viral protein. | 04-15-2010 |
| 20100093825 | Bicycloester derivative | 04-15-2010 |
| 20100099733 | Method for obtaining a stable dispersion of benzoyl peroxide - Powder containing benzoyl peroxide is readily wetted by contacting the powder with a liquid containing one or more of a polyol, a polyol ether, and a low-carbon organic alcohol. | 04-22-2010 |
| 20100137402 | N-[(4,5-DIPHENYL-2-THIENYL)METHYL]AMINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION - The subject of the present invention is compounds corresponding to formula (I): | 06-03-2010 |
| 20100152273 | LOW-VISCOUS ANTHRACYCLINE FORMULATION - The present invention relates to formulations comprising an anthracycline compound and an aromatic or heterocyclic compound. | 06-17-2010 |
| 20100160406 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES - The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using these compositions to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases. | 06-24-2010 |
| 20100160407 | THERAPEUTIC SUBSTITUTED CYCLIC LACTAMS - Disclosed and described herein is a compound having a formula (I) therapeutic methods, medicaments, and compositions related thereto are also disclosed. | 06-24-2010 |
| 20100173969 | THERAPEUTIC AGENT - Provided are agents and methods for use in depleting serum amyloid P component (SAP) from a patient in need thereof. | 07-08-2010 |
| 20100179210 | NOVEL ENANTIOMERICALLY PURE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS - The present invention relates to an enantiomerically pure (+)-trans-enantiomer of a compound represented by the following formula (I): wherein R | 07-15-2010 |
| 20100197759 | Administration of dithiolane compounds for photoprotecting the skin - Dithiolane compounds having the structural formula (I): | 08-05-2010 |
| 20100204296 | Novel Polymorphs of Darifenacin Free Base and its Hydrobromide Salt - The present invention provides a novel and stable amorphous form of darifenacin free base, process for preparation, pharmaceutical compositions, and method of treating thereof. The present invention further provides a novel and stable polymorphic form of darifenacin hydrobromide, process for preparation, pharmaceutical compositions, and method of treating thereof. | 08-12-2010 |
| 20100249205 | Metabolites of Wortmannin Analogs and Methods of Using Same - Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein. | 09-30-2010 |
| 20100292293 | THERAPEUTIC SUBSTITUTED LACTAMS - Disclosed herein are compounds having a formula: (I) Compositions, methods, and medicaments related thereto are also disclosed. | 11-18-2010 |
| 20100305185 | DIAGNOSTIC METHOD - It has been demonstrated that the level of HBP increases in individuals that subsequently develop severe sepsis. Accordingly, the level of HBP, HBP/WBC ratio or HBP/NC ratio in an individual can be used to determine whether or not an individual is at risk of developing severe sepsis. | 12-02-2010 |
| 20100324110 | Self Solidifying Bioerodible Barrier Implant - Provided are bioerodible compositions that can be implanted into cavities of mammalian tissue as a liquid or semi-liquid and which solidify upon exposure to body temperature of the mammal. The implants erode over a prescribed period of time and elute a drug. The implants also form a seal with the skin or mucosa surrounding the cavity to prevent the entry of bacterial pathogens. | 12-23-2010 |
| 20110021597 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 01-27-2011 |
| 20110021598 | CONTROLLED RELEASE FORMULATIONS - The invention relates to a controlled release formulation for an oral cytokine inhibitor of interleukin-1 beta converting enzyme. | 01-27-2011 |
| 20110092562 | Method for wetting a powder containing benzoyl peroxide - Powder containing benzoyl peroxide is readily wetted by contacting the powder with a liquid containing water and one or more water-soluble organic solvents in a concentration sufficient to reduce the surface tension of the liquid to 64 dynes/cm or less. | 04-21-2011 |
| 20110105581 | OPHTHALMIC FORMULATIONS CONTAINING SUBSTITUTED GAMMA LACTAMS AND METHODS FOR USE THEREOF - The invention provides ophthalmic formulations containing well-defined substituted gamma lactams. The formulations described herein are useful in treating a variety of ocular diseases related to ocular hypertension, such as for example, glaucoma. | 05-05-2011 |
| 20110124703 | MOLECULES COMPRISING A BIS(HETEROARYL)MALEIMIDE BACKBONE, AND USE THEREOF IN THE INHIBITION OF DDE/DDD ENZYMES - The invention concerns molecules with a bis-(heteroaryl)maleimide structure and having inhibiting characteristics with respect to enzymes with a catalytic pocket comprising the invariant amino acids D, D and E or D, D and D, such as transposases, RAG recombinases or retroviral integrases. The invention also concerns the use of said molecules for in vitro, ex vivo or in vivo inhibition of transposases, RAG recombinases and retroviral integrases such as HIV integrase, as well as the use of said molecules in the treatment of diseases associated with these enzymes in an animal or human host, in particular in the treatment of AIDS. | 05-26-2011 |
| 20110144180 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents - The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same. | 06-16-2011 |
| 20110190369 | Substituted Pyrrole Derivatives and Their Use as HMG-CO Inhibitors - The present invention relates to substituted pyrrole derivatives, which can be used as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Compounds disclosed herein can function as cholesterol lowering agents and can be used for the treatment of cholesterol-related diseases and related symptoms. Processes for the preparation of disclosed compounds are provided, as well as pharmaceutical compositions containing the disclosed compounds, and methods of treating cholesterol-related diseases and related symptoms. | 08-04-2011 |
| 20110263672 | Metabolites of Wortmannin Analogs and Methods of Using the Same - Novel metabolites of wortmannin and wortmannin analogs and their use in inhibiting PI-3 kinase activity in mammals and the treatment and prevention of cancer or tumor formation in a subject are described herein. | 10-27-2011 |
| 20110275692 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS - A compound comprising | 11-10-2011 |
| 20110313015 | Fludioxonil Derivatives - The present invention relates to the novel fludioxonil derivatives, to processes for their preparation, to their use for controlling unwanted microorganisms, in particular phytopathogenic fungi, or to their use for controlling unwanted broad-leaved weeds and weed grasses of useful plants in each case in crop protection, in the domestic and hygiene field and in the protection of materials, and also to crop protection compositions comprising these fludioxonil derivatives. | 12-22-2011 |
| 20120022125 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS - In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. | 01-26-2012 |
| 20120022126 | Method Of Treating Diabetes Mellitus - The invention provides methods of treating a diabetic subject comprising administering a glucosylceramide synthase inhibitor to the subject. | 01-26-2012 |
| 20120046332 | COMPOSITIONS AND METHODS FOR TREATING CORNEAL HAZE - Disclosed herein are compositions and methods for treating corneal haze. Compositions and methods of use comprise therapeutically effective amounts of compounds that agonize the EP2 and/or EP4 receptor. Administration of the disclosed compounds can prevent and treat corneal haze development. | 02-23-2012 |
| 20120046333 | Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis - Methods and compositions of PI-3 kinase inhibitors and their use in inhibiting PI-3 kinase activity in mammals and the treatment of fibrosing syndromes in a subject are described herein | 02-23-2012 |
| 20120046334 | PYRROLIDINE-SUBSTITUTED FLAVONES AS RADIO-SENSITIZERS FOR USE IN THE TREATMENT OF CANCER - The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer. | 02-23-2012 |
| 20120088809 | 1-(2-ALKYL-2,3-DIHYDRO-BENZOFURAN-4-YL)-PYRROLIDIN-3-YLAMINE ACYL COMPOUNDS - This invention provides new 1-(2-alkyl-2,3-dihydro-benzofuran-4-yl)-pyrrolidin-3-ylamine acyl compounds, their use for the treatment or prevention of melatoninergic disorders and its compositions. | 04-12-2012 |
| 20120122949 | ULTRA-HIGH STRENGTH INJECTABLE HYDROGEL AND PROCESS FOR PRODUCING THE SAME | 05-17-2012 |
| 20120122950 | LIBRARIES OF 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES FOR DRUG DISCOVERY - New compounds are continually being sought for the treatment and prevention of disorders. The invention relates to 1-(sulfonyl)-N-phenyl-pyrrolidine 2-carboxamides which can be used in the search for, and identification of, new lead compounds that could modulate the functional activity of a biological target. | 05-17-2012 |
| 20120142751 | METHODS FOR THE PRODUCTION OF BILIVERDIN - The present invention relates to compositions and methods for the production of biliverdin and methods of treatment and prevention. In particular, the invention concerns methods for producing biliverdin in yeast, especially | 06-07-2012 |
| 20120245214 | SLOW INFUSION OF SULCARDINE AND ITS SALTS - A composition comprised of an active agent that is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide or a pharmaceutically acceptable salt thereof is intravenously administered to a subject, substantially evenly over a period of greater than about 15 minutes, to avoid disadvantageous hemodynamic effects, including systemic diastolic and systolic hypotension, to can occur with rapid intravenous or even short-term infusion administration of the active agent. | 09-27-2012 |
| 20120309810 | TREATMENT OF ATRIAL FIBRILLATION - Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is | 12-06-2012 |
| 20120316216 | PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS - The present invention relates to the use of a compound of formula 1, | 12-13-2012 |
| 20130131137 | INSECTICIDAL COMPOUNDS - The invention relates to compounds of formula (I) where A | 05-23-2013 |
| 20130137743 | AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE - The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described. | 05-30-2013 |
| 20130137744 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS - In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. | 05-30-2013 |
| 20130150424 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS - The present invention relates to (S)-proline sulfonamide compounds of formula (I) | 06-13-2013 |
| 20130225649 | COMPOUNDS FROM ANTRODIA CINNAMOMEA AND USE THEREOF - The present invention relates to compounds from | 08-29-2013 |
| 20130237581 | 3-PHENOXYMETHYLPYRROLIDINE COMPOUNDS - In one aspect, the invention relates to compounds of formula I: | 09-12-2013 |
| 20130237582 | PHARMACEUTICAL COMBINATION OF PACLITAXEL AND A CDK INHIBITOR - The present invention relates to a pharmaceutical combination comprising paclitaxel, or its pharmaceutically acceptable salt; and at least one cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof, for use in the treatment of triple negative breast cancer (TNBC). The present invention relates to a method for the treatment of breast cancer, particularly triple negative breast cancer, by administration to a patient in need thereof, a therapeutically effective amount of a pharmaceutical combination comprising a cytotoxic antineoplastic agent, paclitaxel, and at least one cyclin dependent kinase (CDK) inhibitor; wherein said combination on administration exhibits synergistic effects. | 09-12-2013 |
| 20130331426 | pH-SENSITIVE COMPOSITIONS FOR DELIVERY OF BETA LAPACHONE AND METHODS OF USE - Disclosed herein are compounds comprising a polymer conjugated with a pH-sensitive prodrug of beta-lapachone, wherein the compound is capable of forming a micelle, and wherein the pH-sensitive prodrug comprises a pH-sensitive linker selected from the group consisting of: an aryl imine and an aliphatic imine. Also provided are micelles comprised of such polymer-prodrug conjugates. Further provided are methods for treating cancer with the micelles. | 12-12-2013 |
| 20140005247 | CHROMENE DERIVATIVES | 01-02-2014 |
| 20140051742 | Lipophilic Curcumin Analogs And Methods Of Inhibiting HIV-1, Treating Latent HIV In The Brain, And Preventing HIV-Mediated Cognitive Decline And HIV Dementia - Compounds having formulas (I) to (VIII), salts thereof, or combinations thereof and pharmaceutical compositions comprising one or more these compounds are described herein for the treatment of HIV and neurodegenerative effects caused by HIV. Also provided herein are methods and a kit for inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia comprising administering the compounds having the formulas (I) to (VIII) and pharmaceutical compositions comprising the compounds having these formulas. The compounds having formulas I through VIII are curcumin analogs which are advantageously characterized as having anti-retroviral, neuroprotective, anti-glucosidase, and anti-HIV integrase properties. In one aspect, the pharmaceutical composition is delivered intranasally. | 02-20-2014 |
| 20140073682 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS - In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. | 03-13-2014 |
| 20140080886 | Methods for Treating HCV - Pan-genotypic HCV inhibitors are described. This invention also relates to methods of using these inhibitors to treat HCV infection. | 03-20-2014 |
| 20140121260 | NOVEL CONJUGATES OF POLYUNSATURATED FATTY ACIDS WITH AMINES AND THERAPEUTIC USES THEREOF - The present application discloses conjugates comprising an aminic moiety covalently linked to a hydrophobic moiety, through an amidic bond, which are selective inhibitors of COX-2 enzyme and can be beneficially used in the treatment of various inflammatory disease or disorder and cancer. | 05-01-2014 |
| 20140135373 | NOVEL ESTERS OF N-ACYLATED DERIVATIVES OF AMINO ACIDS AND ISOSORBIDE, METHOD FOR PREPARING SAME, AND USE THEREOF IN COSMETICS AND AS DRUG - Compound with formula (I), wherein R′ and R″ represent a hydrogen atom, a monovalent radical with formula (IIa), or a monovalent radical with formula (IIb), it being understood that at least one of the R′ or R″ radicals does not represent a hydrogen atom and that when the R′ and R″ radicals do not represent a hydrogen atom, R′ and R″ are identical; method for preparing and using in cosmetics and as a drug. | 05-15-2014 |
| 20140142159 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS - The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) | 05-22-2014 |
| 20140171481 | SOLID COMPOSITIONS - The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. | 06-19-2014 |
| 20140179752 | METHODS OF TREATING SOFT TISSUE DEFECTS - The specification discloses compositions and methods for treating a soft tissue defect of an individual. | 06-26-2014 |
| 20140179753 | COMPOUNDS FROM ANTRODIA CINNAMOMEA AND USE THEREOF - The present invention relates to compounds from | 06-26-2014 |
| 20140275203 | Method for Inhibiting Differentiation of Osteoclast and Pharmaceutical Composition Comprising Thereof - The present invention is for method of treating metabolic bone disease, new compounds and pharmaceutical compositions comprising the active ingredients having inhibition effects on osteoclast differentiation. The pharmaceutical composition comprising new compounds according to the present invention can be used as medicines for treating metabolic bone diseases such as bone metastatic cancer, solid cancer bone metastasis, musculoskeletal complication by solid cancer bone metastasis, hypercalcemia by malignant tumor, multiple myeloma, primary bone tumor, osteoporosis, rheumatoid arthritis, osteoarthritis, periodontal disease, inflammatory resorption of alveolar bone, inflammatory resorption of bone, and Paget's disease. | 09-18-2014 |
| 20140288144 | NOVEL ESTERS OF N-ACYL DERIVATIVES OF AMINO ACIDS AND DIOLS, METHOD FOR PREPARING SAME, AND USE THEREOF IN COSMETICS AND AS A DRUG - A compound of formula (I): R′—O-A-O—R″″, in which R′ and R″ are a hydrogen atom or a monovalent radical of formula (IIa), or a monovalent radical of formula (IIb), it being understood that at least one of the radicals R′ or R″ is not a hydrogen atom and that, when none of the radicals R′ and R″ is a hydrogen atom, R′ and R″ are identical, and in which A is a divalent radical of formula (III): —CH(X1)-[C(X2)(X3)]p-CH(X4) in which X1, X2, X3 and X4 are identical or different and are either a hydrogen atom or a methyl radical or an ethyl radical, and p is an integer greater than or equal to 1 and less than or equal to 6. Also the method for preparing the compound of formula (I) and to the use thereof in cosmetics and as a drug. | 09-25-2014 |
| 20140357691 | Methods of Treating Ocular Diseases Using Derivatives of Lipoic Acid - Dithiol compounds and derivatives thereof are disclosed. The agents are useful for treating ocular disease, especially presbyopia and cataract. | 12-04-2014 |
| 20140364478 | PLANT DISEASE CONTROL COMPOSITION - To provide a plant disease control composition having excellent control effect against plant diseases. | 12-11-2014 |
| 20150011602 | STABILIZED PHARMACEUTICAL DOSAGE FORMS COMPRISING ATRASENTAN - The present disclosure relates to: (a) stabilized pharmaceutical dosage forms comprising atrasenstan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent; (b) methods of using such pharmaceutical dosage forms to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods. | 01-08-2015 |
| 20150038545 | HYDROXYPHENYL PYRROLE COMPOUNDS CONTAINING AN HYDROXAMIC ACID AS HDAC INHIBITORS AND MEDICINAL APPLICATIONS THEREOF - The present invention refers to compounds derived from hydroxyphenyl 1H-pyrrole rings, which have the following formula (I): | 02-05-2015 |
| 20150038546 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS - The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. | 02-05-2015 |
| 20150051261 | Methods of Treating Fatty Liver Disease - The disclosure provides methods for treating fatty liver disease and associated conditions by inhibiting the synthesis of glucosphingolipids, as exemplified by the use of glucosylceramide synthase substrate analogs. | 02-19-2015 |
| 20150051262 | NMDA RECEPTOR MODULATORS AND USES THEREOF - Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of diseases and disorders, such as learning, cognitive activities, and analgesia, particularly in alleviating and/or reducing neuropathic pain. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed. | 02-19-2015 |
| 20150073031 | ATRASENTAN MANDELATE SALTS - The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method. | 03-12-2015 |
| 20150111943 | HYDROXYMETHYLFURFURAL DERIVATIVE - The hydroxymethylfurfural derivative is represented by the general formula (A) (wherein, R is selected from the group consisting of the following formula (I), (II) HOOCCH | 04-23-2015 |
| 20150111944 | INSECTICIDAL COMPOUNDS - The invention relates to compounds of formula (I): | 04-23-2015 |
| 20150126574 | ATRASENTAN MANDELATE SALTS - The present disclosure relates to: (a) mandelate salts of atrasentan, (b) pharmaceutical compositions comprising an atrasentan mandelate salt, and, optionally, one or more additional therapeutic agents; (b) methods of using an atrasentan mandelate salt to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising a first pharmaceutical composition comprising an atrasentan mandelate salt, and, optionally, a second pharmaceutical composition comprising one or more additional therapeutic agents; (d) methods for the preparation of an atrasentan mandelate salt; and (e) atrasentan mandelate salts prepared by such method. | 05-07-2015 |
| 20150141480 | CARBOHYDRATE-SELECTIVE RECEPTORS - The present invention is directed to a new class of synthetic carbohydrate receptor compounds comprising Formula I as described herein: (I). Other aspects of the present invention relate to pharmaceutical compositions and pharmaceutical delivery vehicles comprising the compound of Formula (I) The present invention is also directed to methods of treatment and diagnosis that involve the administration of a compound of Formula (I). | 05-21-2015 |
| 20150336940 | THERAPEUTIC SUBSTITUTED PYRROLES - Disclosed herein are compounds of the formula: | 11-26-2015 |
| 20150344460 | N-SUBSTITUTED 3,4-BIS (CATECHOL) PYRROLE COMPOUNDS, AND THE PREPARATION AND USE THEREOF IN THE TREATMENT OF CANCER - The present invention relates to a compound of formula (I) in which: —m is an integer from 0 to 3, preferably from 0 to 2; n is an integer from 0 to 3, preferably from 0 to 2; m+n≧1; EAG is an electro-attractive group chosen independently from among a halogen atom, an NO | 12-03-2015 |
| 20150366197 | SYMMETRICAL MARINOPYRROLE DERIVATIVES AS POTENTIAL ANTIBIOTIC AGENTS - Symmetrical marinopyrrole derivatives are disclosed herein, as is a synthetic route for producing these compounds. Also disclosed are methods of using symmetrical marinopyrrole derivatives to treat bacterial pathogens, like MRSE, MSSA and MRSA. | 12-24-2015 |
| 20150368222 | SUBSTITUTED CHROMAN COMPOUNDS AS CALCIUM SENSING RECEPTOR MODULATORS - The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention. | 12-24-2015 |
| 20160024006 | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS - Disclosed herein are compounds of formula (I) | 01-28-2016 |
| 20160031811 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS - Disclosed herein are compounds of formula (I) | 02-04-2016 |
| 20160060216 | LACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASES AND CONDITIONS - Disclosed herein are compounds of formula (I) | 03-03-2016 |
| 20160068519 | INHIBITORS OF THE ENZYME UDP-GLUCOSE: N-ACYL-SPHINGOSINE GLUCOSYLTRANSFERASE - This invention relates to novel inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of UDP-glucose: N-acyl-sphingosine glucosyltransferase. | 03-10-2016 |
| 20160074363 | METHODS FOR IMPROVING LIPID PROFILES USING ATRASENTAN - The present disclosure is directed to methods for reducing cardiovascular risk in a human subject by administering atrasentan, or a pharmaceutically acceptable salt thereof, in an amount sufficient to effect a reduction of about 5% or more in one or both of (a) total serum cholesterol, relative to the subject's baseline total serum cholesterol, and (b) serum LDL cholesterol, relative to the subject's baseline serum LDL cholesterol. | 03-17-2016 |
| 20160115123 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS - In various embodiments, the present invention provides cycloalkyl pyrrolidine compounds and methods for their use in the treatment and/or prevention of various diseases, conditions and syndromes, including central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter. | 04-28-2016 |
| 20160115125 | SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B - Inhibitors of HBV replication of Formula (ID) | 04-28-2016 |
| 20160120842 | AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE - The hemitartrate salt of a compound represented by the following structural formula: | 05-05-2016 |
| 20160128980 | METHODS OF TREATING CKD USING PREDICTORS OF FLUID RETENTION - The disclosure relates to methods of treating chronic kidney disease and diabetic nephropathy using predictors of fluid retention to minimize the risk of adverse events. The methods disclosed are particularly useful in treatments involving endothelin receptor antagonists, and more particularly, atrasentan and pharmaceutically acceptable salts thereof. | 05-12-2016 |
| 20160150781 | COMPOSITIONS FOR POST-HARVEST TREATMENT AND RELATED METHODS | 06-02-2016 |
| 20160166542 | INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE | 06-16-2016 |
| 20160168088 | 1-[1-(BENZOYL)-PYRROLIDINE-2-CARBONYL]-PYRROLIDINE-2-CARBONITRILE DERIVATIVES | 06-16-2016 |
| 20160193184 | METHOD FOR INDUCTION OF A HEAT SHOCK PROTEIN, ANTI-STRESS OR REGULATION OF AN AUTONOMIC NERVE | 07-07-2016 |
